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Immune landscape in Burkitt lymphoma
reveals M2-macrophage polarization and
correlation between PD-L1 expression and
non-canonical EBV latency program
Massimo Granai1,2†, Lucia Mundo1†, Ayse U. Akarca3, Maria Chiara Siciliano1, Hasan Rizvi4, Virginia Mancini1,
Noel Onyango5, Joshua Nyagol6, Nicholas Othieno Abinya5, Ibrahim Maha7, Sandra Margielewska8, Wenbin Wi8,
Michele Bibas9, Pier Paolo Piccaluga10, Leticia Quintanilla-Martinez2, Falko Fend2, Stefano Lazzi1,
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Abstract
Background: The Tumor Microenviroment (TME) is a complex milieu that is increasingly recognized as a key factor
in multiple stages of disease progression and responses to therapy as well as escape from immune surveillance.
However, the precise contribution of specific immune effector and immune suppressor components of the TME in
Burkitt lymphoma (BL) remains poorly understood.
Methods: In this paper, we applied the computational algorithm CIBERSORT to Gene Expression Profiling (GEP)
datasets of 40 BL samples to draw a map of immune and stromal components of TME. Furthermore, by multiple
immunohistochemistry (IHC) and multispectral immunofluorescence (IF), we investigated the TME of additional
series of 40 BL cases to evaluate the role of the Programmed Death-1 and Programmed Death Ligand-1 (PD-1/PD-
L1) immune checkpoint axis.
Results: Our results indicate that M2 polarized macrophages are the most prominent TME component in BL. In
addition, we investigated the correlation between PD-L1 and latent membrane protein-2A (LMP2A) expression on
tumour cells, highlighting a subgroup of BL cases characterized by a non-canonical latency program of EBV with an
activated PD-L1 pathway.
Conclusion: In conclusion, our study analysed the TME in BL and identified a tolerogenic immune signature
highlighting new potential therapeutic targets.
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Background
Over recent years, the understanding of the biology of
B-cell lymphomas has advanced significantly with the
identification of the role played by the tumour micro-
environment (TME) in lymphomagenesis [1, 2]. The
TME of B-cell lymphomas mainly contains variable
numbers of mesenchymal stem cells, immune cells and
soluble factors. The complex interplay between tumour
cells and TME regulates tumorigenesis and provides
novel targets for immunotherapies [3, 4]. In aggressive
lymphomas, particularly in BL, due to their high prolifer-
ation rate, intensive chemotherapy is required to coun-
teract proliferation and dissemination of neoplastic cells.
Unfortunately, these burdensome treatments are not as
effective in elderly and immunocompromised patients
[5]. Furthermore, in equatorial Africa, where BL is the
most common childhood cancer, the prognosis of BL is
still poor because the intensive therapeutic regimens
often result in a severe neutropenia, with fatal conse-
quences in resource poor settings [6–10]. Shortcomings
of current BL therapies make the exploration of new
therapeutic avenues a substantial and reasonable aim [7].
Therefore, a proper characterization of the TME in BL
might be helpful to identify alternative therapeutic
targets.
One of the histological hallmarks of BL is the high
content of tumour-associated macrophages (TAMs) in-
volved in apoptotic tumour cell clearance that confer the
so-called starry-sky appearance [11]. Although little is
known about the functional status of macrophages and
their impact on tumour immune response in BL, TAMs
may function as potential mediator of tumour progres-
sion through secretion of chemokines, cytokines and ex-
pression of immune checkpoint-associated proteins as
PD-L1 [12, 13].
The expression of PD-L1 in B-cell lymphoma re-
mains controversial, especially in BL. Indeed, PD-L1
has been reported in 80% of BL cases (8 out of 10)
by Majzner [14]. However, this result was not repro-
duced by others [15]. Moreover, the role of the anti-
genic signature of Epstein Barr virus (EBV) in
modulating the tumour microenvironment and the
expression of immune-tolerant proteins has not been
analysed in any of these studies. These different and
somehow discordant results may be due to the di-
verse latency program of EBV infected cells and thus
to different patterns of viral genes expression.
The constitutive association between EBV and BL, es-
pecially with endemic Burkitt lymphoma raises questions
regarding the role of the virus in altering and actively
shaping the tumour microenvironment [16–20]. Indeed,
EBV orchestrates a variety of complex mechanism
favouring the escape of lymphoma cells from anti-
tumour immune responses while promoting the creation
of niches in which tumour cells may find support for
their growth and survival [19–22].
Computational methods such as GEP deconvolution
allow high sensitivity discrimination of cell subsets
within complex tissues, as tumours [23]. These ap-
proaches provide quantitative/ functional information
also on rare tumour-infiltrating elements, offering the
unprecedented opportunity of reanalysing available gen-
omic data and identifying the immune signature. Here,
we applied the computational algorithm CIBERSORT to
GEP datasets of 40 BL samples previously published by
our group [24], including endemic BL (eBL), sporadic
BL (sBL) and immudeficiency associated BL (idBL) cases,
to draw a map of immune and stromal components of
TME. Finally, in order to validate GEP preliminary data,
we applied multiplex immunohistochemistry to an add-
itional cohort of 24 cases. These results were further
supported by Vectra analysis of additional 16 BL by im-
munofluorescence. Thus, a total of 80 BL cases were in-
cluded in the study.
In addition, we investigated the PD-1/PD-L1 pathway
activation status and the contribution of EBV in PD-L1
induction as alternative mechanism responsible for im-
mune evasion.
Methods
CIBERSORT and gene set enrichment analyses
A CIBERSORT-based deconvolution of GEP datasets
(GSE26673) from 40 BL samples (13 eBLs, 21 sBLs, 6
idBLs; discovery cohort), previously published [24], was
carried out using a 547-gene signature matrix custom-
ized for characterizing tissue sample immune cell com-
position, according to CIBERSORT instructions (https://
cibersort.stanford.edu/) [23]. Briefly, normalized gene
expression data were used to infer the relative propor-
tions of 22 types of infiltrating immune cells while gene
expression datasets were prepared using standard anno-
tation files and data uploaded to the CIBERSORT web
portal (http://cibersort.stanford.edu/), with the algorithm
run using the default signature matrix at 1000 permuta-
tions. Gene set enrichment analysis (GSEA) was run on
GSE26673.
Multiplex immunohistochemistry
Multiplex immunohistochemistry was performed on 24
FFPE BL cases (12 eBL, 8 sBL and 4 idBL; validation co-
hort 1) which were retrieved from the Departments of
Histopathology, University College Hospital, London
(UK); Medical Biotechnologies, University of Siena, Siena
(Italy); University of Nairobi, Nairobi (Kenya) and Isti-
tuto Lazzaro Spallanzani, Rome (Italy). The diagnosis of
BL was issued by expert hematopathologists following
the criteria described in the revised 4th edition of World
Health Organization classification of tumours of
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Haematopoietic and Lymphoid Tissue [25]. Single im-
munohistochemistry for the diagnostic antibodies, for
EBV antigens and EBV in situ hybridization was carried
out on the Bond III Autostainer (Leica, Microsystems,
Newcastle upon Tyne, UK) by following the manufac-
turer’s instructions.
By applying multiplex immunostaining (IHC), we in-
vestigated the simultaneous expression of: a) CD68
(Abcam, ab 955, 1:150) brown, CD-163 (Abcam,
Ab87099, 1:100) red and C-Maf (Abcam, Ab243901, 1:
150,) blue; b) PD-1 (Abcam, NAT105, 1:100) brown and
CD8 (Leica Biosystem,4B1, 1:200) red and Granzyme B
(Abcam134933, marker for T- cell activation) blue c)
PD-L1 (ab238697, Abcam, 1:100) brown, CD-163
(Abcam, Ab87099, 1:100) red and MYC (Abcam,
Ab32072, Y69 clone, 1:150) in blue;. The triple immuno-
staining was assessed as previously described [26]. The
colour assignment and staining location are: a) PD-L1
brown/membranous; CD-163 red/membranous; C-MYC
blue/nuclear b) PD-L1, brown/membranous; CD163 red/
membranous; C-Maf blue/nuclear; c) PD-1 brown/mem-
branous; CD8 red/membranous and Granzyme B blue/
nuclear. Tissue sections from the same set of cases and
without antibody/chromogens were used as negative
control.
The percentage of each cell population characterized
by multiplex immunostaining was calculated by counting
the individual cell types in 10 hpf using a 40x objective
(NIKON Eclipse E400).
Multiplex immunofluorescence staining
Multiplex immunofluorescence (mIF) was carried out on
16 formalin fixed paraffin embedded (FFPE) endemic BL
cases (validation cohort 2), belonging to set of samples
previously studied and well characterized for EBV la-
tency program [27].
Multiplex IF was applied to simultaneously detect
the expression of: a) CD68 (Abcam, ab 955, 1:150)
and CD163 (Leica Biosystem, 10D6, 1:200); b) PD-L1
(Dako, clone 22C3, 1:100) and CD163 (Leica Biosys-
tem, 10D6, 1:200); c) PD-L1 and EBV-LMP2A
(Abcam, clone 15F9, ab59028, 1:200). These double
stainings use red and green or magenta and green
chromogens. The colour assignment and staining lo-
cation are: a) CD68 red/membranous; CD163 green/
membranous; b) PD-L1, green/membranous and
CD163, pink/membranous or PD-L1, green/membran-
ous and CD163, red/membranous; c) PD-L1, red;
LMP2A green/ membranous. The staining procedure
was established according to previously published
work [28]. Tissue sections from the same set of cases
and without antibody/fluorophore were used as nega-
tive control. Multiplex IF staining reaction and image
analysis (including quantification of antibodies expres-
sion) were performed using the Vectra 2.0 system
(PerkinElmer, Waltham, MA) and Tissue FAXSFluo
slide scanning system (TissueGnostics, Vienna
Austria) based on a Zeiss Axio Imager Z2 upright
epifluorescence microscope.
Results
EBV status
EBV status and the viral proteins expression in all the
study cases are reported in Table 1. In particular, in the
discovery cohort EBV was positive in all of the eBL, in 6
out of 21 sBL and in 5 out of 6 idBL.
In the validation cohort 1, all of the eBL cases
(12/12) were EBV positive, of which 10 expressed
only EBNA1 by IHC while the remaining two were
characterized by a non-canonical latency of EBV
with the expression of both EBNA1 and LMP2A.
Only two out of the 8 sBL cases were EBV positive
showing a latency I expression pattern with the sole
positivity of EBNA1. All of the idBL cases (4/4) were
EBV positive and showed a latency of type I. In the
validation cohort 2, all the eBL cases were EBV posi-
tive, with 11 out of 16 cases showing an EBV type I
latency, while the remaining 5 cases exhibited a non-
canonical EBV latency consisting of EBNA1 and
LMP1 expression in one case and EBNA1 and
LMP2A in the other 4.
Table 1 EBV status and the viral protein expression. Note: NA stands for not available
EBER/EBNA1+ EBNA1+/LMP1+ EBNA1+/LMP2A+ EBNA1+/LMP1+/LMP2A+ EBV- Total
Discovery cohort eBL 13 NA NA NA – 13
sBL 6 NA NA NA 15 21
idBL 5 NA NA NA 1 6
Validation cohort 1 (mIHC) eBL 10 – 2 – – 12
sBL 2 – – – 6 8
idBL 4 – – – – 4
Validation cohort 2 (mIF) eBL 11 1 4 – – 16
51 1 6 – 22 80
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CIBERSORT identifies M2-polarized macrophages as the
most representative TME component in BL
The computational algorithm CIBERSORT to GEP data-
sets from BL samples revealed a heterogeneous reactive
milieu with slight differences in tumour microenviron-
ment among the three BL subtypes (eBL, sBL and idBL),
most likely reflecting their underlying immunological
status. The analysis showed that macrophages with a M2
profile were the most represented population followed
by CD8-positive T-lymphocytes and CD4 follicular T-
helper cells. In contrast, regulatory T-cells and M1 mac-
rophages were poorly represented (Fig. 1).
Multiplex IHC showed M2 macrophage polarization,
cytotoxic T cells exhaustion and PD-L1 expression in
Burkitt lymphoma cells
The analysis confirmed a shift towards M2 phenotype
(CD68 + CD163+/c-maf +) in all BL cases of validation
cohort 1 ranging from 60 to 80% of total TAMs (Table 2,
Fig. 2a). In particular, the evaluation of M1 macro-
phages, defined by CD68+, CD163-, c-maf- cells showed
very similar values among the series ranging from 20 to
40% of total TAMs. CD8/ PD1/ Granzyme B staining
highlighted that the vast majority of CD8+ T cells co-
expressed PD-1 ranging from 60 to 80 and 50% to 70%
of total tumor infiltrating cytotoxic T cells for eBL and
idBL respectively (insert Fig. 2a; Table 2). Interestingly,
sBL cases, in which EBV was negative to a greater extent
(6 out of 8 cases) showed a markedly lower PD1 expres-
sion on CD8 positive T cells (from 35 to 50% of total
CD8+ cells; Table 2).
The vast majority of TAMs in eBL and idBL cases
expressed PD-L1 ranging from 65 to 80% and from 55
to 75% (Fig. 2b, Table 2). Interestingly, PD-L1 expression
on TAMs in sBL showed lower values (from 20 to 40%;
Table 2). In addition, C-Myc/PD- L1/CD163 triple stain-
ing also disclosed clusters of MYC/PD-L1 double posi-
tive cells in 2 eBL cases characterized by expression of
LMP2A. PD-L1 expression in these cases was focal and
heterogeneous with a degree of intensity from weak to
strong in 10–30% of the total tumor cells, clustering
with TAMs (Fig. 2b). The co-expression of PD-L1 and
LMP2A in scattered neoplastic cells was then confirmed
by double IF (insert Fig. 2b), identifying a possible
Fig. 1 CIBERSORT algorithm. Analysis of 22 immune cell populations profiled by a previous GEP dataset (GSE26673) in BL tumor biopsies. The
heat map figure has been generated by CIBERSORT webserver. The analysis showed that macrophages with a M2 profile were the most
represented population followed by CD8-positive T-lymphocytes and CD4 follicular helper cells. In contrast, regulatory T-cells and M1
macrophages were poorly represented
Table 2 mIHC for TAMs and PD-L1 expression on 24 BL samples (validation cohort 2) stained for PD-L1, CD68, CD163 and c-maf;
mIHC for cytoxic T cells on 24 BL samples (validation cohort 2) stained for PD1, CD8 and granzyme B
mIHC for PD-1/PD-L1 expression and macrophage polarization
eBL (n = 12) sBL (n = 8) iBL (n = 4)
TAM M1 (CD68+/CD163-/c-maf−) 20–40% 30–40% 20–30%
M2 (CD68+/CD163+/c-maf+) 60–80% 60–70% 70–80%
PD-L1 TAMs (PD-L1+/CD163+) 65–80% 20–40% 55–75%
BL cells (MYC+/PD-L1+) 10–30% 0–10% 0–10%
Exhausted cytotoxic T cells CD8+/PD1+/granzyme B- 60–80% 20–40% 60–80%
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Fig. 2 Macrophage polarization and PD-L1 expression on TAMs: (a) CD68 (brown), CD163 (red), c-maf (blue). The majority of TAMs express M2
phenotype markers (CD163+, c-maf+). (O.M: 10x). Inset: CD8 (red), Granzyme B (blue) and PD-1(brown), pattern of PD1 expression on cytotoxic T cells.
(b) C-MYC (blue),PD-L1 (brown), CD163 (red); the majority of TAMs in eBL and idBL cases expressed PD-L1, in addition triple staining disclosed clusters
of C-MYC/PD-L1 double positive cells in 2 cases characterized by co-expression of LMP2A (Inset double IF) clustering with TAMs (O.M: 40x)
Fig. 3 Immunofluorescence staining for Tumor-associated Macrophage Polarization in BL. (a) CD68 (red) (b) CD163 (green). Nuclei were stained
with DAPI. c shows merge of A,B pictures. (d) Example of total macrophage count by Vectra analysis in one case
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correlation between EBV and LMP2A in PD-L1 induc-
tion. Of note, EBV negative BL (6 out of 24 cases) and
conventional BL cases with canonical EBV type I latency
characterized by the sole expression of EBNA1 (16 out
of 24 cases) showed low or absent PD-L1 positivity ran-
ging from 0 to 10% of total tumor cells. These findings
indicate that PD-L1 checkpoint activation is more likely
related to an unusual latency program of EBV rather
than to the EBV presence itself.
Multiplex immunofluorescence confirmed the prevalence
of M2 macrophages and revealed a heterogeneous PD-L1
expression
Tissue samples were studied by mIF and analysed by
VECTRA to quantify macrophages and PD-L1 expres-
sion on 16 BL samples (validation cohort 2) stained for
PD-L1, CD68 and CD163.
In all the cases in validation cohort 2 the M2 macro-
phages were the most represented population ranging from
66 to 78% of total TAMs (Fig. 3), thus confirming the
CIBERSORT and mIHC results. In addition, the vast major-
ity of them were positive for PD-L1 with a range of expres-
sion from 35 to 70% of total macrophages (Fig. 4; Table 3).
Discussion
Although multiple studies have investigated TME and
PD-L1 expression in B-cell lymphomas, only limited,
small studies have been conducted in BL [14–16].
In the present study, we extensively evaluated the
TME composition, activation status and expression of
inhibitory immune checkpoints both on the inflamma-
tory infiltrate and neoplastic cells of BL tumors
including eBL, sBL and idBL cases. Thus, we investigated
PD-L1 expression and the contribution of EBV in foster-
ing the activation of the PD1-PD-L1 axis. The influence
of the microenvironment on cell proliferation and de-
struction varies greatly according to the inherent histo-
type of the lymphoma cell type [29–31]. In particular,
Hodgkin lymphoma (HL) tissue often consists of
relatively few monoclonal cancer cells but at least 90%
non-malignant cells (e.g., regulatory T cells), contribut-
ing to a rather unique surrounding immune ecosystem.
On the other hand, BL seems to be largely devoid of
such a supportive cellular environment, although the
high content of Tumor-Associated Macrophages
(TAMs) might play a distinct, specific, important role in
neoplastic progression through secretion of chemokines,
cytokines and immune checkpoint-associated proteins as
PD-L1 [12, 13].
In the recent decade a model has been developed to
describe the complex mechanism of macrophage activa-
tion as a polarization towards two opposite states,
namely M1 and M2, with pro-inflammatory and pro-
tumoral properties respectively [32–36]. TAM density in
particular M2-TAMs have been associated with tumor
progression and poor prognosis in DLBCL [37, 38].
In the present work, we identified a polarization towards
a M2 phenotype of TAMs in all cases by applying three
different approaches (CIBERSORT, mIHC and mIF) re-
gardless of the subtype of BL, and thus, of EBV status.
These cells, intimately associated with the neoplastic
cells, constituted also the major source of PD- L1, which
may inhibit the overall inflammatory response and allow
the neoplastic cells to evade antitumor immunity. How-
ever, the lower rate of PD-L1 expression on TAMs in
sBL, as compared with eBL and idBL, which are fre-
quently associated with EBV, may suggest a role of the
virus in inducing PDL1 expression.
PD-L1 is a major regulator of T cell function and, after
engaging PD-1, leads to an altered functional state of T-
cells, namely T cell exhaustion [39]. In this regard, we
found that in eBL and idBL the vast majority of the CD8+
infiltrating T cells expressed PD-1 highlighting an adaptive
immune response resistance mechanism in such cases.
However, PD-L1 limits an antitumor immune response
by signalling not only through PD-1 but also with nother
receptor, namely CD80 (also named B7–1), expressed on
the surface of activated CD8+ T cells [40–42]. The
Fig. 4 Immunofluorescence staining for PD-L1 and TAMs. a CD163 (red), b PDL-1 (green) merge (c). The vast majority of TAMs exhibited M2
phenotype markers (CD163+) and expressed PD-L1 to a greater extent
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influence of the PD-L1/PD-1 interaction on CD8+ T cell
function has been extensively characterized and is known
to limit CD8+ T cell responses by inhibiting TCR signal-
ling, thus restricting CD8+ T cell survival, proliferation,
and cytokine production. On the other hand, the role of
the PD-L1/CD80 pathway on CD8+ T cell functions in BL
is unknown, and thus, further studies are necessary.
In addition, the role of PD-1 expression in Tumor In-
filtrating Lymphocytes (TILs) on both lymphoid and epi-
thelial malignancies is controversial [38]. PD-1
expression in CD8+ cells has been associated with the
selective suppression of cytotoxic lymphocytes in EBV
positive nasopharyngeal carcinoma [43]. On the other
hand, the PD-1+ TILs have also been described to lack
Tim-3 expression in papilloma virus positive cancers,
and thus possibly representing activated T-cells [44].
Emerging evidence in EBV-related malignancies indi-
cates that the virus possesses the ability to actively shape
the tumor microenvironment, and favours its escape
from anti-tumor immune responses through a variety of
complex mechanisms [18]. EBV may induce a strong up-
regulation of PD-L1 expression both directly on the sur-
face of human primary monocytes, or indirectly on neo-
plastic cells, through its viral proteins LMP-1 which
interfere with downstream cellular signalling (i.e. AP1;
JAK/STAT) [45, 46] to induce an immune tolerant niche
for EBV- related tumors [47–49]. LMP-2 may also exert
its tolerogenic effect by affecting crucial cell-cycle regu-
lating pathways such as PI3K/Akt wich plays a critical
role in PD-L1 expression [50–52].
Although PD-L1 expression has been largely investi-
gated in B cell lymphomas, the distinction of its expres-
sion in cellular microenviroment and/or in tumour cells
has not been made in most studies [1–4].
Here we showed that EBV in BL might induce PD-L1
expression on tumor cells in a minority of cases charac-
terized by a non-canonical latency with LMP2A positiv-
ity. On the other hand, it might influence PD-L1
upregulation on TAMs also in cases with canonical EBV
latency I. However, the prevalence of M2 macrophages
as primary constituent of the TME in BL is a constant
finding in all BL subtypes and thus, macrophage
polarization towards a pro-tumoral state seems an event
related to the intrinsic characteristics of the tumor.
Conclusions
In conclusion, although based on a small sample size,
our findings may provide insights on BL TME and its
underlying mechanisms of immune evasion. The cross-
talk between different actors including TAMs, PD-1/PD-
L1, T-cells, viral antigens and tumor cells may result in
the failure of innate immunity in BL which results in M2
polarization. Despite the good response to conventional
therapy of BL, our data may provide a rationale for new
immunotherapeutic strategies.
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